久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Novartis' biosimilar rituximab delayed in US pharmatimes
    May 04, 2018
    Novartis' Sandoz division announced today that the US FDA has issued a complete response letter regarding the Biologics Licensing Application (BLA) for its proposed biosimilar rituximab, meaning that approval of the drug has been delayed in the country.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service